Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer
- 1 May 2016
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119 (2) , 312-318
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Pancreatic AdenocarcinomaNew England Journal of Medicine, 2014
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA, 2013
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJAMA, 2010
- Neoadjuvant Therapy for Pancreatic CancerJournal of Gastrointestinal Surgery, 2008
- Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic AcidClinical Cancer Research, 2008
- Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II TrialJournal of Clinical Oncology, 2008
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaThe Oncologist, 2007
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX fociMolecular Cancer Therapeutics, 2006
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001